Physician profile
Amee Dharia
NPI 1316391352
$2,925.62
in general payments reported to CMS, 2019-2025
19 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $135 · 2021: $763 · 2022: $1,030 · 2023: $258 · 2024: $146 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $671.31 | 2021-2025 | Watchman Flx |
| Atricure, INC. | $454.54 | 2022-2023 | |
| Amgen INC. | $270.84 | 2021-2025 | Repatha |
| Medtronic, INC. | $242.88 | 2021-2025 | Advisa Dr Mri Surescan |
| Heartflow, INC. | $239.67 | 2025 | |
| Preventice Services, LLC | $149.85 | 2021 | |
| Merck Sharp & Dohme LLC | $149.25 | 2022-2023 | Verquvo |
| Pfizer INC. | $140.15 | 2020-2024 | |
| Esperion Therapeutics, INC. | $114.40 | 2021 | |
| Astellas Pharma US INC | $112.73 | 2021 | |
| Medtronic Vascular, INC. | $105.82 | 2020 | |
| Janssen Pharmaceuticals, INC | $86.48 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $65.59 | 2021-2022 | |
| Abbott Laboratories | $40.10 | 2023 | Assurity |
| Edwards Lifesciences Corporation | $20.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.46 | 2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $15.64 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $14.31 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $13.60 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amee Dharia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.